ZVRA · Zevra Therapeutics, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 5, 2026TL;DR. Zevra reported Q2 2026 net revenue of $39.7 million (up 53% YoY), driven by $30.2 million in U.S. MIPLYFFA sales, and ended the quarter with $260.2 million in cash. The company has requested re-examination of its European arimoclomol MAA following a CHMP negative opinion, while advancing its celiprolol Phase 3 DiSCOVER trial.
- + Q2 2026 net revenue of $39.7 million rose 53% YoY, led by $30.2 million in MIPLYFFA U.S. sales.
- + MIPLYFFA U.S. revenue grew 40% YoY and 23% sequentially versus Q1 2026.
- + Cash position strengthened to $260.2 million, up roughly $23.4 million from March 31, 2026.
- + MIPLYFFA U.S. intellectual property extended with Orange Book listing through 2041.
- + Operating expenses fell to $21.0 million from $24.2 million a year ago, driven by lower SG&A.
- − CHMP issued a negative opinion on the arimoclomol MAA, prompting reexamination.
- − Q2 2026 results include a $6.4 million non-cash mark-to-market loss on warrant liabilities.
- − Global EAP net reimbursements of $9.0 million are expected to be highly variable quarter-to-quarter outside France.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ZVRA
this stock
Zevra Therapeutics, Inc.
|
$648.17M | +22.4% | +350.9% | 11.6 | 9.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ZVRA | -3.1% | -9.0% | +13.0% | -6.6% | +22.4% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -2.4% | -9.2% | +0.8% | -6.0% | +10.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.